Search
INGN 225
go.drugbank.com/drugs/DB05325InvestigationalINGN 225 is a therapeutic consisting of a cancer patient's own immune cells treated with an adenovector carrying the human p53 gene, Ad-p53.
ND7001
go.drugbank.com/drugs/DB05142ExperimentalND7001, a selective PDE2 inhibitor is in clinical trials for the treatment of depression. ND7001 is a solid.
Cirazoline
go.drugbank.com/drugs/DB09202ExperimentalIt is an agonist of α1A, partial agonist of α1B and α1D, and a nonselective antagonist of α2. … It is believed that this combination of properties could make cirazoline an effective vasoconstricting agent.
Categories: Adrenergic alpha-1 Receptor AgonistsIsepamicin
go.drugbank.com/drugs/DB13540ExperimentalCategories: Antibacterials for Systemic Use, Antiinfectives for Systemic UseSisunatovir
go.drugbank.com/drugs/DB15674InvestigationalSisunatovir is under investigation in clinical trial NCT04267822 (Study of RV521 in the Treatment of Adult Subjects Who Have Undergone HCT With an URTI With RSV).
Apitegromab
go.drugbank.com/drugs/DB16096InvestigationalApitegromab is under investigation in clinical trial NCT03921528 (An Active Treatment Study of SRK-015 in Patients With Type 2 or Type 3 Spinal Muscular Atrophy).
Minzasolmin
go.drugbank.com/drugs/DB18961InvestigationalMinzasolmin is under investigation in clinical trial NCT05543252 (An Extension Study to Evaluate the Long-term Efficacy, Safety and Tolerability of Minzasolmin (UCB0599) in Study Participants With Parkinson's
9-amino-n-[3-(dimethylamino)propyl]acridine-4-carboxamide
go.drugbank.com/drugs/DB02842Experimental9-amino-n-[3-(dimethylamino)propyl]acridine-4-carboxamide is an inactive derivative of the antitumour agents N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA) and 9-amino-DACA.
AAV8-RK-RetGC
go.drugbank.com/drugs/DB32389ExperimentalAAV8-RK-RetGC is an adeno-associated virus (AAV) viral vector platform with a serotype 8 capsid with a complementary DNA (cDNA) of the human GUCY2D gene encoding RetGC.
Nemiralisib
go.drugbank.com/drugs/DB16253InvestigationalNemiralisib is under investigation in clinical trial NCT03345407 (Dose Finding Study of Nemiralisib (GSK2269557) in Subjects With an Acute Moderate or Severe Exacerbation of Chronic Obstructive Pulmonary